patients with confirmed multiple sclerosis (MS) after serial administrations of the macrocyclic
gadolinium-based contrast agents (GBCAs), gadoterate meglumine and gadobutrol.
Materials and methods This retrospective study was approved by the institutional review
board and informed consent was waived. A review of our PACS database for the period from
March 1, 2007 to July 31, 2016 revealed 158 confirmed MS patients who received …